Mounjaro - A New Treatment forType 2 Diabetes
Nicole Spears, Market Manager – Georgia, Lilly USA, LLC
Mounjaro is the first and only approved glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA). It is a single molecule designed to bind to both GIP and GLP-1 receptors. Mounjaro is a prescription medicine for adults with type 2 diabetes used along with diet and exercise to improve glycemic control.